In the present study, we therefore aimed at evaluating whether epoxomicin may reduce cardiac hypertrophy and improve cardiac function in a genetically-engineered mouse model of hypertrophic cardiomyopathy (HCM), which carries a mutation in Mybpc3, encoding the myofilament protein cardiac myosin-binding protein C. The corresponding human c.772G>A MYBPC3 mutation is one of the most frequent HCM mutations (found in 13% unrelated HCM patients; Olivotto et al., 2008) and associated with a bad prognosis (Richard et al., 2003). This evidence concerns the gene MYBPC3 and hypertrophic cardiomyopathy.